GlobeNewswire

ERYTECH Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F

Del

LYON, France, March 29, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2018 “Document de Référence” for the year ended December 31, 2018, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2018 with the U.S. Securities and Exchange Commission (SEC).             

These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also available free of charge, by sending a postal request to the registered offices of ERYTECH Pharma, 60 Avenue Rockefeller, 69008 in Lyon (France).

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers.

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
investors@erytech.com

+33 1 44 71 98 52
ERYTECH@newcap.eu

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

LGC CAPITAL announces conditional approval of an amended private placement financing of $10,400,000 with Arlington Capital LP25.4.2019 14:00:00 CESTPressemelding

MONTRÉAL, April 25, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC") is pleased to announce that it has obtained conditional approval from the TSX Venture Exchange for its previously announced financing with Arlington Capital (please refer to LGC’s press release dated January 24, 2019). Since that announcement, both parties have agreed to increase the financing to $10.4 million from the previously announced $8 million. Pursuant to the private placement, Arlington Capital will subscribe for a total of 104,000,000 common shares of LGC at a price of $0.10 per share. As a result of this private placement, Arlington Capital will, on closing, become LGC’s largest shareholder holding 19.97% of LGC’s issued and outstanding common shares. There are no warrants with this financing. Use of proceeds are to accelerate LGC’s group of companies’ business plan for the current calendar year. As previously announced, on closing of the private placement, LGC will pay a 3% finde

Ascom adds ‘talk before walk’ wireless speech function to new release of Ascom teleCARE IP25.4.2019 14:00:00 CESTPressemelding

New feature helps reduce caregivers’ walking time; enables more streamlined workflows in elderly care facilities BAAR, Switzerland, April 25, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflow solutions, has added wireless speech functionality to its latest version of the Ascom teleCARE IP emergency call system. The new feature promises to help reduce the time spent by staff walking to investigate calls from residents in continuing and elderly care facilities. Ascom teleCARE IP has always had hardwired speech functionality. But by making it wireless, residents can simply use their normal mobile phones to communicate directly with caregivers via Ascom teleCARE IP. Caregivers can communicate with residents while on the go, and can deal with residents’ calls before walking to investigate. The newly released (Ascom teleCARE IP 12) is available globally. The latest version also features several technical enhancements inclu

Rafael Santana to Succeed Ray Betler as Wabtec President and CEO25.4.2019 13:32:00 CESTPressemelding

WILMERDING, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Wabtec Corporation (NYSE: WAB) today announced Rafael Santana will become president and CEO of the company, effective July 1, 2019. Santana, who will also become a Wabtec board member, will succeed Ray Betler, who will retire as a Wabtec executive and board member. Santana, 47, joined Wabtec earlier this year as president and CEO of the company’s Freight segment following the merger of Wabtec and GE Transportation, where he served as president and CEO of the General Electric unit. Wabtec Executive Chairman Al Neupaver said: “This transition comes at a time of strength at Wabtec given our diverse portfolio, excellent management team, and strong backlog and balance sheet. The selection of Rafael to succeed Ray is the culmination of a thorough CEO succession planning process that evaluated both internal and external candidates. Rafael is the right leader for this role − bringing to Wabtec a passion for operational excellence and technolo

Bombardier Provides Preliminary First Quarter 2019 Financial Results, Updates 2019 Guidance25.4.2019 12:00:00 CESTPressemelding

First Quarter 2019 Consolidated Performance(1) Revenues expected to be ~$3.5B; driven lower by timing of aircraft deliveries, slower project ramp up at Transportation, and unfavourable currency translation Adjusted EBITDA(2) and adjusted EBIT(2) expected to be ~$265M and ~$170M, respectively, due to lower revenues and revised cost estimates on Transportation projects Free cash flow usage(2) expected to be ~$1.0B, supporting working capital investments 2019 Guidance(3) Update Consolidated revenue guidance now expected to be ~$1.0B lower at ~$17.0B, representing ~10% growth year over year, excluding currency effects and divestitures Aerospace businesses on track; Consolidated revenue guidance changed mainly due to revised Transportation outlook Consolidated adjusted EBITDA expectations reduced from $1.65-1.80B to $1.50-1.65B, representing a ~20% increase year over year Consolidated adjusted EBIT expectations reduced from $1.15-1.25B to $1.0-1.15B Consolidated free cash flow guidance rema

First Quarter 2019 Results Conference Call24.4.2019 19:55:00 CESTPressemelding

AURORA, Ontario, April 24, 2019 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG ) (NYSE: MGA ) FIRST QUARTER 2019 RESULTS CONFERENCE CALL THURSDAY – MAY 9, 2019 8:30 AM ET DIAL IN NUMBERS North America: 1-800-954-0587 International: 1-312-281-2942 Webcast: www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until May 16, 2019 North America: 1-800-558-5253 International: 1-416-626-4100 Reservation No.: 21922562 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations louis.tonelli@magna.com 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations nancy.hansford@magna.com 905-726-7108

Flashpoint Strengthens Intelligence Platform with New Dashboards and Analytics, Expanded Collections and Tailored Alerting by Industry24.4.2019 16:00:00 CESTPressemelding

Company Significantly Expands Use-Case Driven Business Risk Intelligence (BRI) Offerings NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Flashpoint, the global leader in Business Risk Intelligence (BRI), today announced new innovations and enhancements that help multiple teams bolster cybersecurity, confront fraud, detect insider threats, enhance corporate and physical security, and address third-party risk. The new innovations and enhancements strengthen Flashpoint Intelligence Platform, which grants access to the company’s archive of finished intelligence reports, data from illicit forums, marketplaces, chat services, paste sites, technical data, card and account shops, and vulnerabilities, in a finished intelligence experience. The platform scales Flashpoint’s internal team of specialized, multilingual intelligence analysts’ ability to quickly provide responses to customers. “As a long-time Flashpoint customer, I have seen many iterations of the company’s platform, technology, and coll